Predict your next investment

Aptima company logo
Corporation
SOFTWARE (NON-INTERNET/MOBILE) | Business Intelligence, Analytics & Performance Mgmt Software
aptima.com

See what CB Insights has to offer

Founded Year

1995

Stage

Loan | Alive

Total Raised

$3.5M

Last Raised

$3.5M | 2 yrs ago

About Aptima

Aptima aims to optimize the performance of humans operating in technology-intensive, mission critical settings including defense, intel, aviation, law enforcement, and healthcare.

Aptima Headquarter Location

12 Gill Street Suite 1400

Woburn, Massachusetts, 01801,

United States

781-935-3966

Latest Aptima News

Hologic's COVID-19 Tests Detect Omicron Variant

Nov 30, 2021

Hologic's COVID-19 Tests Detect Omicron Variant Hologic, Inc. (Nasdaq: HOLX) announced today that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of the coronavirus that causes COVID-19. Author: Hologic, Inc. (Nasdaq: HOLX) announced today that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of the coronavirus that causes COVID-19. Initially identified in South Africa and subsequently in a number of African, European and North American countries, the Omicron variant (B.1.1.529) contains approximately 30 mutations. Hologic conducted an analysis of genetic sequences from more than 175 Omicron-infected samples obtained through GISAID (Global Initiative On Sharing All Influenza Data, https://www.gisaid.org/ ) and determined that none of the new mutations occur within regions of the genome targeted by Hologic's Aptima ® SARS-CoV-2 Assay, Aptima® SARS-CoV-2/Flu Assay or Panther Fusion® SARS-CoV-2 Assay. Hologic has also received data from clinical users in Europe indicating that the Aptima SARS-CoV-2 assay detected Omicron COVID-19 infections in samples from inbound air travelers. "We fully expect that SARS-CoV-2 will continue to evolve, as that is the natural path for viruses," said Kevin Thornal, president of the Diagnostic Solutions Division at Hologic. "We designed our assays with this in mind, and as a result, we are confident that the Omicron variant will not impact the performance of our assays." Aptima and Panther Fusion tests run on Hologic's fully automated Panther® and Panther Fusion systems, respectively, which provide initial results in approximately three hours and can process more than 1,000 tests in 24 hours. Hologic has provided more than 130 million SARS-CoV-2 assays to its laboratory customers, making a significant contribution to the global testing supply. More than 2,700 Panther systems are installed in clinical diagnostic laboratories around the world. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com . Forward-Looking Statements This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic's Aptima® SARS-CoV-2 Assay, Aptima® SARS-CoV-2/Flu Assay and Panther Fusion® SARS-CoV-2 Assay and the Panther® and Panther Fusion® systems. In addition, there can be no assurance that the products will be manufactured in adequate quantities to meet demand, be commercially successful, or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based. Hologic, Aptima, Panther, Panther Fusion and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries. SOURCE: Hologic, Inc.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aptima

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aptima is included in 1 Expert Collection, including Digital Health.

D

Digital Health

11,671 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Aptima Patents

Aptima has filed 40 patents.

The 3 most popular patent topics include:

  • Educational technology
  • Artificial intelligence
  • Educational psychology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/27/2020

11/30/2021

Machine learning, Educational psychology, Learning, Educational technology, Pedagogy

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/27/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/30/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Machine learning, Educational psychology, Learning, Educational technology, Pedagogy

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Aptima Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aptima Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.